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This is the ﬁrst report to present a clinical comparison of unrelated cord blood transplantation (CBT) and HLA-
matched sibling allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid
leukemia (CML) in advanced stage (accelerated phase or blast crisis). A total of 32 consecutive patients with
advanced CML received unrelated CBT (n ¼ 16) or HLA-matched sibling allogeneic peripheral blood stem cell
or bone marrow transplantation (allo-PBSCT/BMT) (n ¼ 16) between 2002 and 2011. The median day to
neutrophil engraftment and the median day to platelet engraftment were longer in the unrelated CBT group.
The cumulative incidence of grades 1 to 2 acute graft-versus-host disease (aGVHD), grades 3 to 4 aGVHD, and
chronic graft-versus-host disease did not differ signiﬁcantly between the 2 cohorts. The cumulative incidence
of transplantation-related mortality (TRM) at day þ180 was higher in CBT group (37.5% versus 12.5%,
P ¼ .013). The risk of relapse was lower in CBT patients compared with that of allo-PBSCT/BMT patients (14.2%
versus 42.7%, P ¼ .03). The long-term survival in CBT group patients was slightly better than that of allo-
PBSCT/BMT group, although the difference did not reach statistical signiﬁcance: the 5-year overall survival
for CBT patients and allo-PBSCT/BMT patients was 62.5% and 48.6%, respectively (P ¼ .10), whereas the 5-year
leukemia-free-survival rate was 50% and 40.5%, respectively (P ¼ .12). Our comparisons suggest that patients
with advanced CML receiving unrelated CBT had a lower relapse rate, a slightly better long-term survival, but
a higher early TRM than those receiving HLA-matched related allo-PBSCT/BMT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Patients with chronic myeloid leukemia (CML) in accel-
erated phase (AP) and blast crisis (BC) are generally consid-
ered as having a poor prognosis. Treatment with tyrosine
kinase inhibitors (such as imatinib, nilotinib, and dasatinib)
has improved survival in advanced CML modestly, but the
long-term survival is still unsatisfactory [1-4]. Allogeneic
hematopoietic stem cell transplantation (HSCT) remains the
only curative option and induces long-term molecular and
cytogenetic remission in patients with advanced CML [5-7].
However, the majority of the published studies are based on
the results obtained by HLA-matched related allogeneic
peripheral blood stem cell (PBSC) or bone marrow (BM)
transplantation (allo-PBSCT/BMT), and few studies have
evaluated the treatment effect of unrelated cord blood
transplantation (CBT). The advantages of CBT include rapid
availability, absence of donor risk, and the relatively lower
risk of graft-versus-host disease (GVHD) with preserved
graft-versus-malignancy effects. In the present retrospective
single-center study, we report a clinical comparison of
unrelated CBT and HLA-matched sibling allo-PBSCT/BMT for
patients with CML in the advanced stage.edgments on page 1712.
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13.09.008PATIENTS AND METHODS
Between March 22, 2002 and April 4, 2011, a total of 16 consecutive
patients with advanced CML (9 in AP, 7 in BC) received unrelated CBT, and
16 (10 in AP, 6 in BC) received HLA-matched sibling allo-PBSCT/BMT (donor
cells: 1 of BM, 6 of PBSC, 9 of PBSC plus BM) in Anhui Provincial Hospital. The
details of patients’ characteristics and transplantation procedures are
summarized in Table 1. Patients received unrelated CBT because of no
suitable related donor (HLA-identical or 1-antigenemismatched). Umbilical
cord blood (UCB) units that were serologically matched for  4 of 6 HLA
antigens and which contained at least 3  107 nucleated cells/kg and
1.2  105 CD34þ/kg of recipient body weight before freezing were obtained
from the cord blood bank at the China Cord Blood Bank Network. The units
were not depleted of T lymphocytes. The choice to transplant 1 versus 2 UCB
units was based solely on cell dose criteria. If a UCB unit with the minimum
cell dose was not available, the patient underwent transplantation with
2 partially HLA-matched UCB units, which needed to have a minimum
cryopreserved dose of 3.5  107 nucleated cells/kg and 2  105 CD34þ/kg,
respectively.
A total of 10 patients received single UCB grafts, and the other 6
patients received double UCB grafts. For patients who received unrelated
CBT, 14 patients (87.5%) received a myeloablative conditioning regimen of
total body irradiation (total 12 Gy, 4 fractions) and cyclophosphamide
(60 mg/kg daily for 2 days) (age  18 years or no remission after relapse)
(n ¼ 11, 68.8%) or busulfan (.8 mg/kg every 6 hours for 4 days) and
cyclophosphamide (60 g/kg daily for 2 days) (BUCY2) (age < 18 years or
prior radiotherapy, which would presuppose a high risk of toxicity)
(n ¼ 3, 18.7%). High-dose cytarabine (2.0 g/m2 every 12 hours for 2 days)
(11 of 14, 78.6%) was added to the myeloablative conditioning regimen to
kill the leukemia cells maximally, especially in extramedullary sites.
Reduced-intensity conditioning was used for patients who were unable to
tolerate fully myeloablative conditioning because of extensive prior
treatment and comorbid diseases, such as suboptimal visceral organ
function, or recent life-threatening infection. Only 2 CBT patients (12.5%)
received a reduced-intensity conditioning regimen of ﬂudarabine (55 mg/
m2 daily for 3 days), busulfan (.8 mg/kg every 6 hours for 2 days), andTransplantation.
Table 1
Patients’ and Transplantation Characteristics between Unrelated CBT and HLA-Matched Sibling Allo-PBSCT/BMT
Characteristics Unrelated CBT (n ¼ 16) Sibling Allo-HSCT (n ¼ 16) P
Age at transplantation, median (range), yr 25.4 (16 to 43) 33.4 (12 to 53) .75
Sex: male/female 10/6 12/4 .69
Disease stage at diagnosis
Accelerated phase 9 (56.3%) 10 (62.5%) .46
Blast crisis (ALL) 4 (25%) 2 (12.5%)
Blast crisis (AML) 3 (18.7%) 4 (25%)
Disease stage in transplantation
Second chronic phase* 9 (56.3%) 10 (62.5%) .92
Accelerated phase 4 (25%) 5 (31.2%)
Blast crisis (ALL) 1 (6.3%) 0 (0%)
Blast crisis (AML) 2 (12.5%) 1 (6.3%)
Pretransplantation treatment
Systemic chemotherapy 7 (43.7%) 8 (50%) .58
Imatinib 5 (31.3%) 6 (37.5%)
Systemic chemotherapy þ imatinib 4 (25%) 2 (12.5%)
Positive recipient CMV serology before transplantation 12 (75%) 14 (87.4%) .55
Duration from diagnosis to transplantation, median (range), mo 6.5 (3 to 16) 5.3 (1.5 to 10) .63
HLA match (lowest)
6/6 1 (6.3%) 15 (93.8%) .02
5/6 7 (43.7%) 1 (6.3%)
4/6 8 (50%) 0 (0%)
ABO compatibilityy
Match 4 (25%) 9 (56.3%) .18
Major mismatch 10 (62.5%) 3 (18.7%)
Minor mismatch 2 (12.5%) 4 (25%)
Myeloablative conditioning
BUCY2-based conditioning 3 (18.7%) 16 (100%) .03
TBICY-based conditioning 11 (68.8%) 0 (0%)
Reduced-intensity conditioning
FludarabineþBUþTBI 2 (12.5%) 0 (0%)
GVHD prophylaxis
CSAþMMF 12 (75%) 14 (87.4%) .82
CSAþMMFþMTX 0 (0%) 1 (6.3%)
CSAþMMFþATGz 4 (25%) 1 (6.3%)
Total nucleated-cell dose, median (range) ( 107/kg) 3.7 (2.1 to 6.1) 59.2 (36.8 to 89.3) <.001
Total CD34þ cell dose, median (range) ( 105/kg) 2.4 (0.7 to 4.9) 47.6 (19.2 to 127.6) <.001
Total CD3 cell dose, median (range) ( 106/kg) 6.1 (2.87 to 22.2) 78.8 (29.4 to 196.5) <.001
Neutrophil engraftment, median (range), d 22.1 (14 to 35) 12.5 (11 to 14) .01
Platelet engraftment, median (range), d 43.7 (27 to 83) 16.3 (12 to 28) .005
Primary graft failure 0 (0%) 0 (0%)
Acute GVHD, n (% CumInc, 95% CI)
I to II 5 (32.5%, 22.4 to 41.8) 5 (34.2%, 25.9 to 43.6) .89
III to IV 4 (26.3%, 15.2 to 35.9) 2 (13.8%, 6.5 to 21.3) .15
Chronic GVHD, n (% CumInc, 95% CI) 3 (19.5%, 12.7 to 28.6) 6 (39.6%, 29.5 to 48.2) .09
Limited 2 (12.5%) 3 (18.7%)
Extensive 1 (6.3%) 3 (18.7%)
HVOD 1 (6.3%) 0 (0%)
TRM, n (% CumInc, 95% CI) 6 (37.5%, 31.8 to 48.5) 4 (28.6%, 19.8 to 39.2) .26
Relapse, n (% CumInc, 95% CI) 2 (14.2%, 6.8 to 22.3) 6 (42.7%, 34.5 to 51.6) .03
BM relapse 1 (6.3%) 5 (31.3%)
Extramedullary relapse 1 (6.3%) 1 (6.3%)
CBT indicates cord blood transplantation; HSCT, hematopoietic stem cell transplantation; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BU,
busulfan; CY, cyclophosphamide; TBI, total body irradiation; BUCY2, busulfan (.8 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 g/kg daily for
2 days); TBICY, total body irradiation (total 12 Gy, 4 fractions) and cyclophosphamide (60 mg/kg daily for 2 days); CSA, cyclosporine; MMF, mycophenolate
mofetil; MTX, methotrexate; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; HVOD, hepatic veno-occlusive disease; BM, bone marrow; TRM,
transplantation-related mortality; CMV, cytomegalovirus; CumInc, cumulative incidence; CI, conﬁdence interval.
Data presented are n (%) unless otherwise indicated.
* Second chronic phase was deﬁned as<5% blasts in a normohypercellular marrow, with the characteristics of the previous chronic phase with normal values
in peripheral blood and normal physical ﬁndings for at least 1 month. No patients achieved complete cytogenetic response or major molecular response at the
time of transplantation.
y In the major ABO mismatched group patients had isoagglutinins directed against donor A or B antigens, and in the minor ABO mismatch group donors had
isoagglutinins directed against patient A or B antigens.
z ATG was administered in order to facilitate engraftment (2 patients in CBT group with reduced intensity conditioning) or to decrease aGVHD (2 patients in
CBT group and 1 patient in sibling allo-HSCT group with high CD3 cell dose infusion).
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with HLA-matched sibling allogeneic HSCT received a myeloablative
conditioning regimen of BUCY2, and 6 patients (42.9%) also received high-
dose cytarabine.
For GVHD prophylaxis, all patients were given a combination of cyclo-
sporine (Novartis, Stein, Switzerland) and mycophenolate mofetil (Roche,
Basel, Switzerland). Cyclosporine was started at 3 mg/kg intravenously
daily from day 1 to þ30 with target trough levels between 200 and
400 ng/mL, then patients were changed to oral cyclosporine as soon as theycan tolerate oral intake. Mycophenolate mofetil (20 w 30 mg/kg/day) was
given on day þ1. The rapidity of tapering was based on the presence or
absence of GVHD, infectious disease, and relapse risks. In addition to
cyclosporineþmycophenolatemofetil, therewere 4 unrelated CBT patients
and 1 HLA-matched sibling allogeneic HSCT patient who received antith-
ymocyte globulin, and 1 HLA-matched sibling allogeneic HSCT patient
received short-term methotrexate, as a GVHD prophylaxis. Granulocyte-
colony stimulating factor (5 mg/kg/day) was administered intravenously
from day þ6 until neutrophil recovery became durable.
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with an absolute neutrophil count  .5  109/L, and platelet engraftment
was deﬁned as the ﬁrst day when the platelet count was 20  109/L for
7 consecutive days without transfusion support. Chimerismwas assessed by
PCR analysis of short tandem repeat sequences on whole blood weekly (on
the 7th, 14th, 21st day), then on bone marrow monthly. Both acute and
chronic GVHD were diagnosed and graded according to the previously
published criteria [8,9].
Patient-, disease-, and transplantation-related variables of the 2 trans-
plantation groups were compared via chi-square test. Time-to-event
outcomes for neutrophil and platelet engraftment, GVHD, transplantation-
related mortality (TRM), and relapse were estimated using cumulative
incidence curves. The Kaplan-Meier method was used to estimate the
probabilities of the overall survival (OS) and leukemia-free-survival (LFS),
which were compared using the log rank test. A P < .05 was considered
statistically signiﬁcant. Most analyses were performed with SPSS (version
17.0), and the cumulative incidence of relapse was performed with
R statistical software (R Foundation for Statistical Computing, Vienna,
Austria) (because early TRM was a competing risk for relapse).Figure 1. Cumulative incidence of transplantation-related mortality and
relapse. (A) The cumulative incidence of transplantation-related mortality
(TRM) at day þ180 (early TRM) was higher in unrelated CBT group than HLA-
matched sibling allo-PBSCT/BMT group (37.5% [95% CI, 31.8% to 48.5%] versus
12.5% [95% CI, 6.5% to 21.8%], P ¼ .013) (B) The cumulative incidence of relapse
was lower in unrelated CBT patients compared with that of HLA-matched
sibling allo-PBSCT/BMT patients (14.2% [95% CI, 6.8% to 22.3%] versus 42.7%
[95% CI, 34.5% to 51.6%], P ¼ .03) (B).RESULTS
All patients achieved hematopoietic engraftment in both
groups. The median day to neutrophil engraftment and the
median day to platelet engraftment were all longer in the
unrelated CBT group (22.1 days for CBT versus 12.5 days for
allo-PBSCT/BMT, P ¼ .01; 43.7 days for CBT versus 16.3 days
for allo-PBSCT/BMT, P ¼ .005). The day þ100 cumulative
incidence of grades I to II acute GVHD (aGVHD) was 32.5%
(95% conﬁdence interval [CI], 22.4% to 41.8%) for CBT patients
and 34.2% (95% CI, 25.9% to 43.6%) for allo-PBSCT/BMT
patients (P ¼ .89), and grades III to IV aGVHD was 26.3%
(95% CI, 15.2% to 35.9%) for CBT patients and 13.8% (95% CI,
6.5% to 21.3%) for allo-PBSCT/BMT (P ¼ .15). The cumulative
incidence of chronic GVHD (cGVHD) was 19.5% (95% CI, 12.7%
to 28.6%) in the CBT group and 39.6% (95% CI, 29.5% to 48.2%)
in the allo-PBSCT/BMT group (P ¼ .09) (Table 1).
The cumulative incidence of TRMwas 37.5% (95% CI, 31.8%
to 48.5%) and 28.6% (95% CI, 19.8% to 39.2%) in the CBT group
and allo-PBSCT/BMT group, respectively (P ¼ .26). But the
cumulative incidence of TRM at day þ180 (early TRM)
was higher in CBT group than allo-PBSCT/BMT group (37.5%
[95% CI, 31.8% to 48.5%] versus 12.5% [95% CI, 6.5% to 21.8%],
P ¼ .013) (Figure 1A). In the CBT group, 6 transplantation-
related deaths (3 of 9 patients in second chronic phase, and
3 of 7 patients in advanced phase) occurred at a median time
of 73 days after transplantation (range, 40 to 146), including
severe pulmonary bacterial and/or fungal infection (n ¼ 2),
refractory aGVHD combined with severe infection (n ¼ 3),
and hepatic veno-occlusive disease (n ¼ 1). In the allo-
PBSCT/BMT group, 4 patients (2 of 10 patients in second
chronic phase, and 2 of 6 patients in advanced phase) died
because of transplantation-related complications, and the
causes of death were refractory aGVHD in 2 patients (a
median time of 42 days after transplantation), and cGVHD
combined with invasive pulmonary fungal infection in
2 patients (a median time of 406 days after transplantation).
The risk of relapse was lower in CBT patients compared
with that of allo-PBSCT/BMT patients (14.2% [95% CI, 6.8% to
22.3%] versus 42.7% [95% CI, 34.5% to 51.6%], P ¼ .03)
(Figure 1B). Among patients with CBT, only 2 patients who
received myeloablative single UCB graft relapsed: 1 patient
experienced a hematological relapse after 9 months and
achieved complete molecular remission and 100% donor
chimerism after reintroduction of imatinib; another patient
suffered from extramedullary relapse (meningeal involve-
ment and right upper limb leukemic mass) 21 months after
transplantation and achieved second complete remission
after treatment of intrathecal chemotherapy and localirradiation. Among patients with allo-PBSCT/BMT, 6 patients
experienced a hematological relapse at a median of
11 months (range, 4 to 36) after transplantation, and only
2 patients were alive with complete molecular remission
after the treatment of imatinib.
The median follow-up period for survivors was
43.1 months (range, 25 to 68) for CBT patients and
59.7 months (range, 11 to 86) for allo-PBSCT/BMT patients.
The OS and LFS rate in CBT group patients were slightly
better than allo-PBSCT/BMT group, although the difference
did not reach statistical signiﬁcance: the 5-year OS for CBT
patients and allo-PBSCT/BMT patients was 62.5% (95% CI,
51.6% to 72.9%) and 48.6% (95% CI, 39.2% to 59.7%), respec-
tively (P ¼ .10), whereas the 5-year LFS rate was 50% (95%
CI, 42.6% to 58.8%) and 40.5% (95% CI, 29.4% to 50.9%),
respectively (P ¼ .12) (Figure 2A and B).
DISCUSSION
Allo-HSCT from an HLA-identical related donor offers
a potential cure for patients with advanced phase of CML;
however, only one third of eligible patients have a related
Figure 2. Probabilities of overall survival (OS) and leukemia-free survival
(LFS). The 5-year OS (A) for unrelated CBT patients and HLA-matched sibling
allo-PBSCT/BMT patients was 62.5% (95% CI, 51.6% to 72.9%) and 48.6% (95% CI,
39.2% to 59.7%), respectively (P ¼ .10), whereas the 5-year LFS (B) was 50% (95%
CI, 42.6% to 58.8%) and 40.5% (95% CI, 29.4% to 50.9%), respectively (P ¼ .12).
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of cord blood registries has increased the chances of using
unrelated UCBs as an alternative stem cell source. But until
now, there are only 3 clinical studies specially investigated the
role of unrelated CBT for the treatment of CML [10-12].
Investigators in Valencia ﬁrst reported of a small series of
9 patients, and they recently reported an update of 26 adults
with CML, of whom 19 were in the second chronic phase or
advanced phase at the time of a single-unit transplantation
[10,11]. Another study from Japan Cord Blood Bank Network
(JCBBN) reported outcomes in 86 patients with CML, of whom
79 were in the second chronic phase or advanced phase [12].
All these clinical studies concluded that unrelated CBT should
be considered a reasonable alternative for those patients with
CML in need of allo-HSCT who lacked a suitable HLA-matched
donor.
To our knowledge, this is the ﬁrst report to present
a clinical comparison of unrelated CBT and HLA-matched
sibling allo-PBSCT/BMT for patients with CML in advanced
stage. As reported in other series [13-16], transplantation of
CB was associated with slower neutrophil and platelet
recovery than transplantation of BM or PBSC, irrespective of
HLAmatch. JCBBN’s study [12] indicated that a nucleated celldose of more than 3.0  107 per kg was sufﬁcient to achieve
neutrophil (91%) and platelet engraftment (86%), whereas
the lower dose of nucleated cell achieved only 60% and 61%,
respectively. Sanz et al. [11] also showed that the cumulative
incidence of myeloid engraftment was 88% at a median time
of 22 days, and identiﬁed that CD34 þ cells dose at time of
infusion was the main factor associated with myeloid
recovery. In our study, the simultaneous transplantation of
2 partially HLA-matched UCB units (double UCB trans-
plantation) has been used in 6 patients to overcome cell dose
limitations and avoid graft failure.
Our study showed that CBT recipients had a higher inci-
dence of TRM than BMT/PBSCT recipients, especially severe
infection and refractory aGVHD, in the ﬁrst 180 days after
transplantation. Severe infections after CBT may be in large
part attributable to the slower hematopoietic and immune
reconstitutions, and could be increased in case of refractory
aGVHD caused by potent immunosuppressive treatment
[17,18]. Parody et al. [17] evaluated the occurrence of severe
infections in 192 consecutive adult recipients of unrelated
donor allogeneic HSCT, with a detailed analysis of severe
infections after receipt of CBT (n ¼ 44) or BMT/PBSCT
(n ¼ 144), and found that CBT recipients had a higher inci-
dence of severe infections and a higher proportion of
infectious-related mortality during the ﬁrst 100 days after
transplantation. Ponce et al. [19] compared survival of
75 double-unit CBT and 108 related donor transplantation
recipients who underwent transplantation over the same
period for the treatment of hematologic malignancies, and
found that a higher incidence of TRM was seen in CBT recip-
ients in the ﬁrst 6 months after transplantation (21% versus
7%; P ¼ .017). Eapen et al. [20] also found that TRM was
signiﬁcantly higher after 4 to 6/6 HLA-matched UCB trans-
plantations (n ¼ 165) compared to 8/8 HLA-matched PBPC
and BM transplants (n ¼ 1360) with most events (severe
infection, refractory aGVHD, and organ failure) in the UCB
group occurring within 6 months after transplantation (33%
versus 23%; P< .01). For CML, early TRMmay be related to the
disease stage at time of transplantation. Investigators in
Valencia found that TRMwas 41% for patients undergoing CBT
in ﬁrst or second chronic phase (CP), whereas it was 100% for
patients in AP or BC [11]. Results of the JCBBN’s analyses
showed that age was an independent risk factor for TRM, and
the cumulative incidence of TRM in older adults (51 years or
older) at 1 year was 49% and 18% in those younger than
50 years of age [12]. However, in this current study, after
day þ180, the cumulative incidence of TRM was not different
between CBT and BMT/PBSCT groups, perhaps because of the
fact that CBT recipients who survived the ﬁrst 6 months after
transplantation were unlikely to die of TRM [17,19,20].
The present data showed that the relapse rate for
advanced CML patients after unrelated CBT was lower than
with HLA-matched sibling allo-PBSCT/BMT (14.2% versus
42.7%, P ¼ .03). Takahashi et al. [15] compared the results of
unrelated CBT with related BM or PBSC transplantations in
adult patients with hematologic malignancies after myeloa-
blative conditioning regimen, and found that 3-year cumu-
lative incidence of relapse was lower in CBT recipients than
in related BMT/PBSCT recipients (17% versus 26%). A Korean
study [21] also reported the outcomes in children with acute
leukemia who underwent transplantations, and observed
that there was a lower incidence of relapse in the CBT group
than in the BMT/PBSCT group from an HLA-matched related
donor (P ¼ .06). All these observations indicated that unre-
lated CBT might have a stronger graft-versus-leukemia (GVL)
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might contribute to this low relapse rate in CBT recipients.
First, more than half of patients are in second CP phase.
Gutman et al. [22] observed a low relapse rate after mye-
loablative CBT for patients with high-risk acute leukemia or
CML in morphologic complete remission at the time of
transplantation. Sanz et al. [11] found that all 11 patients (in
second CP) who survived UCBT remained CML-free after
a median follow-up of around 8 years. JCBBN’s study [12] also
indicated that patients with an advanced stage (AP and BC) at
CBT showed a trend towards earlier relapse compared to
those in CP at transplantation. Second, there are 6 patients
receiving a double UCB unit in our study. Verneris et al. [23]
suggested that there was a signiﬁcantly lower risk for relapse
in patients who received double-unit transplants compared
with single-unit recipients (19% versus 34% at 5 years), and
revealed that the use of 2 UCB units was associated with
an enhanced GVL effect. Perhaps graftegraft interaction
between the 2 UCB units may be responsible for the apparent
reduced risk of relapse. Third, 7 patients received 1-antigen
mismatched CB transplants and 8 patients received
2-antigen mismatched CB transplants. Some studies have
shown that HLA disparity might have a stronger GVL effect
than HLA-identical sibling donor HSCT. Kanda et al. [24] re-
ported that the incidence of relapse was dramatically
decreased with 1-locusemismatched family member HSCT
compared with matched HSCT for high-risk diseases (19%
versus 47%; P ¼ .004). Eapen et al. [25] demonstrated that
relapse rates were signiﬁcant lower after 2-antigen mis-
matched cord-blood transplants than after allele-matched
BM transplantations (at 6 months: P ¼ .0045; beyond
12 months: P ¼ .0001). Atsuta et al. [26] investigated the
effect of HLA disparity on the outcome of single-unit unre-
lated CBT, and found that a 2-loci mismatch was associated
with a decreased risk of relapse in adult recipients than that
in 6/6 UCB recipients (P ¼ .034).
In conclusion, we demonstrated that patients with
advanced CML receiving unrelated CBT had a lower relapse
rate, a slightly better long-term survival, but a higher early
TRM than HLA-matched related allo-PBSCT/BMT. This is
a nonprospective and nonrandomized study, and the number
of patients is small; further studies and new strategies are
needed to reduce the early TRM of CBT.ACKNOWLEDGMENTS
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